SEC Comment Letter 0000000000-23-005096 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: May 15, 2023 · CIK: 0000890821 · Accession: 0000000000-23-005096
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-38286
Letter
United States securities and exchange commission logo May 15, 2023 Kevin Coveney Chief Financial Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Re:Enveric Biosciences, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed March 31, 2023 File No. 001-38286 Dear Kevin Coveney: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2022 Notes to Consolidated Financial Statements Note 1. Business and Liquidity and Other Uncertainties Reverse Stock Split, page F-9 1.We note your disclosure that on July 14, 2022 you effected a 1-for-50 reverse stock split and that all historical and per share amounts reflected throughout your filing have been adjusted to reflect the reverse stock split. Please clarify whether the adjustments made to your historical 2021 financial statements, which were audited by Friedman LLP, have been audited by your current independent registered public accounting firm. Please advise and provide an updated audit report, as applicable. Refer to Section 4830 of the Division of Corporation Finance’s Financial Reporting Manual as well as the PCAOB Q&A on Adjustments to Prior-Period Financial Statements Audited by a Predecessor Auditor.
FirstName LastNameKevin Coveney Comapany NameEnveric Biosciences, Inc. May 15, 2023 Page 2 FirstName LastName Kevin Coveney Enveric Biosciences, Inc. May 15, 2023 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Frank Wyman at 202-551-3660 or Ibolya Ignat at 202-551-3636 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 15, 2023
Kevin Coveney
Chief Financial Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, Florida 34103
Re:Enveric Biosciences, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed March 31, 2023
File No. 001-38286
Dear Kevin Coveney:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment, we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Form 10-K for Fiscal Year Ended December 31, 2022
Notes to Consolidated Financial Statements
Note 1. Business and Liquidity and Other Uncertainties
Reverse Stock Split, page F-9
1.We note your disclosure that on July 14, 2022 you effected a 1-for-50 reverse stock split
and that all historical and per share amounts reflected throughout your filing have been
adjusted to reflect the reverse stock split. Please clarify whether the adjustments made to
your historical 2021 financial statements, which were audited by Friedman LLP, have
been audited by your current independent registered public accounting firm. Please advise
and provide an updated audit report, as applicable. Refer to Section 4830 of the Division
of Corporation Finance’s Financial Reporting Manual as well as the PCAOB Q&A on
Adjustments to Prior-Period Financial Statements Audited by a Predecessor Auditor.
FirstName LastNameKevin Coveney
Comapany NameEnveric Biosciences, Inc.
May 15, 2023 Page 2
FirstName LastName
Kevin Coveney
Enveric Biosciences, Inc.
May 15, 2023
Page 2
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Frank Wyman at 202-551-3660 or Ibolya Ignat at 202-551-3636 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences